Study on the regulating effect of Ginkgo biloba Extract ( GBE50) Dispersible Tablets on blood lipids in people with cardiovascular and cerebrovascular diseases in the real world
- Conditions
- cardiovascular and cerebrovascular diseases
- Registration Number
- ITMCTR2200006367
- Lead Sponsor
- Shanghai Jiaotong University School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- Not specified
(1) The age is over 18 years old. The gender is not limited.
(2) Subjects with cardiovascular and cerebrovascular diseases who have been treated in the hospital before June 2022, meet the diagnostic criteria for cardiovascular and cerebrovascular diseases (including cerebral infarction, coronary heart disease, and complications such as hypertension, diabetes, dyslipidemia, cardiac insufficiency, etc.);
(3) The subjects had at least baseline and over six months blood lipids, blood routine, liver and kidney function test records.
(1) Subjects with a history of acute or chronic infection, or combined with severe immune system disease or blood system disease;
(2) Subjects with severe cardiac insufficiency;
(3) Subjects with severe liver and kidney complications or other serious primary diseases;
(4) Subjects with a history of mental illness.
Study & Design
- Study Type
- Observational study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Changes in low-density lipoprotein cholesterol LDL-C (mmol/L);
- Secondary Outcome Measures
Name Time Method Changes in High density liptein cholesterol;Changes in triglycercide;Changes in total cholesterol;